Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Economic Analysis of Anti-Rheumatic Medication in an Observational Cohort of Ontario Rheumatoid Arthritis Patients: Coverage with Evidence Development from the Ontario Best Practices Research Initiative

FY 2013-14

Summary
Biologic therapies are an expensive treatment for rheumatoid arthritis. Payers of rheumatoid arthritis medication cost including government, and private insurers make decisions on which drugs to pay for based on economic analysis to determine which drugs provide the best ratio of costs to benefits. Since biologic medications are so expensive, reimbursement decisions concerning these drugs are especially important, because funds are not unlimited and equitable and sustainable distribution must be ensured. Existing economic analysis concerning biologic medications do not represent the group of patients receiving care in Ontario. Randomized control trials use a highly selected group of patients, meaning the results derived from them might not reflect the true costs and benefits of biologic therapies in Ontario. Furthermore, randomized trials typically collect data for 1 year, while rheumatoid arthritis medications may have different costs and benefits over many years, meaning a longer term time horizon is needed. To address this concern we propose to use an observational group of Ontario rheumatoid arthritis patients, followed in routine care in Ontario to determine the costs and benefits of treatment in actual care. We will provide this information by collecting patient data, and linking data to the amount of health care resources used by patients in order to gain an understanding of how different treatments affect health care resource utilization. We will aggregate all the costs and benefits for each patient, then using a predictive model to estimate the total health care costs over each patient's lifetime. Once we have created our model, subsets of patients that receive more costs or benefits for different therapies can be identified. The results of our research will help decision makers ensure that biologic therapies for rheumatoid arthritis remain equitable, available and sustainable. The goal is for the right patient to receive the right medication at the right time. Further, researchers of other chronic diseases could use our methodologies as a model for their own cohort research.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311841
Name
Tatangelo Mark R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Economic Analysis of Anti-Rheumatic Medication in an Observational Cohort of Ontario Rheumatoid Arthritis Patients: Coverage with Evidence Development from the Ontario Best Practices Research Initiative
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Diseases; Coverage With Evidence Development; Economic Analysis; Economic Models; Health Care Resource Utilization; Health Services Research; Observational Cohort; Population Health; Rheumatoid Arthritis
Abstract
Biologic therapies are an expensive treatment for rheumatoid arthritis. Payers of rheumatoid arthritis medication cost including government, and private insurers make decisions on which drugs to pay for based on economic analysis to determine which drugs provide the best ratio of costs to benefits. Since biologic medications are so expensive, reimbursement decisions concerning these drugs are especially important, because funds are not unlimited and equitable and sustainable distribution must be ensured. Existing economic analysis concerning biologic medications do not represent the group of patients receiving care in Ontario. Randomized control trials use a highly selected group of patients, meaning the results derived from them might not reflect the true costs and benefits of biologic therapies in Ontario. Furthermore, randomized trials typically collect data for 1 year, while rheumatoid arthritis medications may have different costs and benefits over many years, meaning a longer term time horizon is needed. To address this concern we propose to use an observational group of Ontario rheumatoid arthritis patients, followed in routine care in Ontario to determine the costs and benefits of treatment in actual care. We will provide this information by collecting patient data, and linking data to the amount of health care resources used by patients in order to gain an understanding of how different treatments affect health care resource utilization. We will aggregate all the costs and benefits for each patient, then using a predictive model to estimate the total health care costs over each patient's lifetime. Once we have created our model, subsets of patients that receive more costs or benefits for different therapies can be identified. The results of our research will help decision makers ensure that biologic therapies for rheumatoid arthritis remain equitable, available and sustainable. The goal is for the right patient to receive the right medication at the right time. Further, researchers of other chronic diseases could use our methodologies as a model for their own cohort research.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tatangelo, Mark R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~